Premium
High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry
Author(s) -
Pyatigorskaya Nadya,
Sharman Michael,
Corvol JeanChristophe,
Valabregue Romain,
YahiaCherif Lydia,
Poupon Fabrice,
CormierDequaire Florence,
Siebner Hartwig,
Klebe Stephan,
Vidailhet Marie,
Brice Alexis,
Lehéricy Stephane
Publication year - 2015
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26218
Subject(s) - parkin , asymptomatic , substantia nigra , lrrk2 , parkinson's disease , medicine , mutation , relaxometry , pathology , gastroenterology , endocrinology , chemistry , magnetic resonance imaging , disease , radiology , biochemistry , spin echo , gene
Objectives The goal of this work was to investigate iron deposition in the basal ganglia and thalamus in symptomatic and asymptomatic leucine‐rich repeat kinase 2 (LRRK2) and Parkin‐associated Parkinson's disease (PD), using R2* relaxometry rate. Methods Twenty subjects with genetic PD (four symptomatic and two asymptomatic Parkin subjects, nine symptomatic and five asymptomatic LRRK2 subjects) were compared with 20 patients with idiopathic PD (IPD) and 20 healthy subjects. Images were obtained at 3 teslas, using multi‐echo T2 and T2* sequences. R2 and R2* values were calculated in the substantia nigra (SN), the striatum, the globus pallidus, and the thalamus. Results The R2* values in the SN were increased in IPD and mutation‐carrying patients as compared with controls and in mutation‐carrying patients as compared with IPD. Asymptomatic mutation carriers showed higher R2* values than controls and did not differ from IPD patients. No changes were seen in the other structures or in R2 values. Conclusion These results are consistent with increased iron load in LRRK2‐ and Parkin‐mutation carriers. The increased R2* in asymptomatic PD‐mutation carriers suggests that iron deposition occurs early during the preclinical phase of the disease. R2* measurements may be used as markers for investigating nigrostriatal damage in preclinical mutation‐carrying patients. © 2015 International Parkinson and Movement Disorder Society